Literature DB >> 8435938

Trichomonas vaginalis: a reemerging pathogen.

P Heine1, J A McGregor.   

Abstract

Infestation with T. vaginalis is a common and potentially morbid infection. In addition to reproductive tract discharge and irritation, infection with this protozoa is increasingly recognized to be associated with reproductive tract complications, including postabortal infection, postcesarean infection, preterm birth, and PROM. Clinical diagnosis is often difficult and newer approaches using specific antigen and nucleic acid technologies will probably replace "wet prep" microscopic techniques. Effective treatments continue to depend on oral metronidazole treatment. Cure of resistant strains, which remain rare, depends on administration of higher, more prolonged doses of metronidazole. Improved understanding of the natural history, pathobiology, diagnosis, and treatment of this common protozoa is urgently needed. Practitioners should consider routinely screening and treating women for trichomoniasis before any reproductive tract surgery (chorionic villi sampling, hysterectomy, cesarean section, dilatation and curettage, therapeutic abortion, and so on), after changing sexual partners, and during pregnancy. Both symptomatic and asymptomatic patients and their sexual contacts should be treated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435938     DOI: 10.1097/00003081-199303000-00019

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  37 in total

1.  Predictors of infection with Trichomonas vaginalis: a prospective study of low income African-American adolescent females.

Authors:  R Crosby; R J DiClemente; G M Wingood; K Harrington; S L Davies; E W Hook; M K Oh
Journal:  Sex Transm Infect       Date:  2002-10       Impact factor: 3.519

2.  Trichomonas vaginalis epidemiology: parameterising and analysing a model of treatment interventions.

Authors:  F J Bowden; G P Garnett
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

3.  Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.

Authors:  T Meri; T S Jokiranta; L Suhonen; S Meri
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

4.  Trichomonas vaginalis virulence against epithelial cells and morphological variability: the comparison between a well-established strain and a fresh isolate.

Authors:  J B Jesus; M A Vannier-Santos; C Britto; P Godefroy; F C Silva-Filho; A A S Pinheiro; B Rocha-Azevedo; A H C S Lopes; J R Meyer-Fernandes
Journal:  Parasitol Res       Date:  2004-06-15       Impact factor: 2.289

5.  Two novel serum-free media for the culture of Trichomonas vaginalis.

Authors:  M E Limoncu; A A Kilimcioğlu; O Kurt; I Ostan; N Ozkütük; A Ozbilgin
Journal:  Parasitol Res       Date:  2006-09-01       Impact factor: 2.289

6.  Diagnosis of Trichomonas vaginalis infection by PCR using vaginal swab samples.

Authors:  G Madico; T C Quinn; A Rompalo; K T McKee; C A Gaydos
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

7.  Comparison of the InPouch TV culture system and Diamond's modified medium for detection of Trichomonas vaginalis.

Authors:  M H Levi; J Torres; C Piña; R S Klein
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

8.  In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis.

Authors:  E M Narcisi; W E Secor
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 9.  Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.

Authors:  Sarah L Cudmore; Kiera L Delgaty; Shannon F Hayward-McClelland; Dino P Petrin; Gary E Garber
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Vaginal and oral microbes, host genotype and preterm birth.

Authors:  Usha Srinivasan; Dawn Misra; Mary L Marazita; Betsy Foxman
Journal:  Med Hypotheses       Date:  2009-12       Impact factor: 1.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.